USPTO serial 87352575
TEVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 15, 2020
- Examiner
- MICHELI, ANGELA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with TEVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Teva Pharmaceutical Industries Limited
Jerusalem, IL
Other trademarks owned by Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
Jerusalem, IL
Other trademarks owned by Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
Jerusalem, IL
Other trademarks owned by Teva Pharmaceutical Industries Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lori Wolfe
Lori Wolfe Teva Pharmaceuticals USA, Inc.400 Interpace ParkwayBuilding AParsippany, NJ 07054Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system | ACTIVE | Sep 21, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Teva Pharmaceutical Industries Limited
- Other trademarks owned by Teva Pharmaceutical Industries Limited
- Other trademarks owned by Teva Pharmaceutical Industries Limited
- Other trademarks in Class 005
- Similar marks named TEVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 9, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 9, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 9, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 9, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 9, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 15, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 15, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 10, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 9, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 5, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 5, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 5, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 5, 2020 | SNEA | SU-EXAMINER'S AMENDMENT WRITTEN | — |
| Oct 30, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 20, 2020 | IUAF | USE AMENDMENT FILED | — |
| Oct 20, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 22, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 21, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 18, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 13, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 13, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 29, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 19, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 19, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 19, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 19, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 15, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 13, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 13, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 13, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 15, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 13, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 13, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 13, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 13, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 13, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 13, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 20, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 26, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 26, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 6, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 17, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 17, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 17, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 17, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 17, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 14, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 14, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2017 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 26, 2017 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 26, 2017 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 23, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 8, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 7, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2017 | NWAP | NEW APPLICATION ENTERED | — |